Evidence map›Paper›PMID 24911892›Full record

ArticleStem cells (Dayton, Ohio)2014

Mesenchymal stem cells differentially modulate effector CD8+ T cell subsets and exacerbate experimental autoimmune encephalomyelitis.

Justin D Glenn, Matthew D Smith, Peter A Calabresi, Katharine A Whartenby

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells (Dayton, Ohio), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Interferon regulatory factors orchestrate CD8International journal of molecular medicine · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Direct modulation of myelin-autoreactive CD4International journal of nanomedicine · 2018
    Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Justin D GlennDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Matthew D Smith
Peter A Calabresi
Katharine A Whartenby
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

Mechanisms by which effector T cells modulate endogenous remyelinationR37NS041435 · NINDS · JOHNS HOPKINS UNIVERSITY · PI CALABRESI, PETER A · 2013 to 2019
$3.0M
NINDS NIH HHS R37 NS041435
6 · The paper itself

Abstract

Mesenchymal stem cells (MSC) have emerged as a promising candidate for inflammatory suppression and disease amelioration, especially of neuro-inflammatory diseases such as multiple sclerosis (MS). Auto-reactive CD4+ and CD8+ T cells acquire pathogenic IFNγ-producing- (Type I) and IL-17A-producing- (Type 17) effector phenotypes in MS and its animal model experimental autoimmune encephalomyelitis (EAE). Although MSC have been extensively demonstrated to suppress pathogenic effector CD4+ T cells and CD4+ T cell-mediated EAE, surprisingly few studies have addressed their modulation of effector CD8+ T cells represented in MS or their impact on CD8+ T cell-mediated EAE. We find that MSC differentially modulate CD8+ T cell development depending on effector T cell subtype. MSC drive activated low-IFNγ producers toward an enhanced high-IFNγ Tc1-like phenotype but strongly inhibit the production of IL-17A and Tc17 polarization in vitro. These observations are underscored by differential MSC modulation of T cell activation, proliferation, and signature transcription factor up-regulation. In addition, effector CD8+ T cells co-cultured with MSC exhibited increased production of IL-2, a molecule known to enhance IFNγ, yet suppress IL-17A, production. Based on these in vitro effects on CD8+ T cells, we next evaluated their impact on the severity of EAE. To better evaluate CD8+ T cells, we immunized mice with MOG37-50 , which is a CD8-targeted epitope. Our results revealed a worsening of disease, consistent with their in vitro stimulation of Tc1 cells. These findings highlight the emerging duality of MSC in immune modulation and provide implications for their future use in immune-related diseases.

Indexed as

Disease ProgressionAnimalsApoptosisCD8-Positive T-LymphocytesCell ProliferationCoculture TechniquesEncephalomyelitis, Autoimmune, ExperimentalFemaleInterferon-gammaInterleukin-2Lymphocyte ActivationMesenchymal Stem CellsMice, Inbred C57BLMyelin-Oligodendrocyte GlycoproteinT-Box Domain ProteinsT-Lymphocyte SubsetsEomes protein, mouseInterferon-gammaInterleukin-2Myelin-Oligodendrocyte GlycoproteinT-Box Domain ProteinsAutoimmuneCD8 T cellExperimental autoimmune encephalomyelitisMesenchymal stem cell

Identifiers

PMID24911892
PMCPMC7568282
OpenAlexW1825093923

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.